AU Health partners with Inflo Health to elevate the radiology follow-up process to optimize the patient experience

CONTACT: Lisa Kaylor, AU Health, 706-755-3160, lkaylor@augusta.edu; Alicia Laszewski, Inflo Health, 954-683-7189, alicia@yourbrandethos.com

AUGUSTA, Ga. (June 13, 2023) – Augusta University Health(AU Health), a comprehensive primary, specialty, and subspeciality healthcare network based in Augusta, Georgia, that serves as the primary teaching affiliate for the Medical College of Georgia, announced today that they are partnering with Inflo Health, a radiology follow-up solution powered by advanced AI and natural language understanding (NLU). Augusta University Health will leverage Inflo Health’s innovative solution to automate the radiology follow-up process for hundreds of thousands of their radiology patients per year.

According to an American College of Radiology study, 60% of radiology imaging follow-ups never get completed. Inflo Health estimates that their platform allows their customers the ability to recapture at least 80% of these missed follow-ups.

“The radiology follow-up process can be challenging and time intensive, with life-changing consequences,” added John Crossgrove, Director of Radiology Services at AU Health. “Inflo Health is a smart and powerful technology that stood out to us during our search for a partner in this area for a multitude of reasons. The ability to automate and close the communication loop with 100% of our providers and patients in this area, across all modalities, without adding additional staff is transformational in supporting our world-class patient care mission and objectives.”

Inflo Health will support all areas within AU Health’s radiology program, including support to close any gaps within the incidental findings program. According to the ACR, incidental findings are defined as “an incidentally discovered mass or lesion, detected by CT, MRI, or other imaging modality performed for an unrelated reason.” Many different forms of cancers are discovered incidentally, and lifesaving therapies can be prescribed much earlier in the tumor development, leading to better patient outcomes.

Dr. Annette Johnson, AU Health’s Chair of Radiology and Imaging commented, “Complexity within health systems contributes to the reality that communication breakdowns are responsible for the majority of safety events in health care environments.  Test results management is a particularly substantial challenge for physicians and other providers, despite their diligence and focused efforts at information management.  Breakdowns in communication of test results occur across the spectrum of clinical settings and can result in delayed diagnoses and harm to patients. Our vision in AU Health Radiology is ‘Better imaging for better health.’ By partnering with Inflo Health, we can further this vision by creating automated processes for identification and tracking of imaging findings that require follow-up—so that we can have a failsafe system for providing timely and potentially life-saving testing and treatment to further ensure the delivery of the very best care for our patients. We are thrilled to have selected Inflo Health as our partner on this journey.”

Angela Adams, CEO of Inflo Health, said, “A recent article published by the American College of Radiology (ACR) cited that over 65% of Emergency Physicians and Radiologists report that their health systems do not have a tracking mechanism for incidental findings today. This is a staggering statistic given the importance of timely identification and communication for healthy patient outcomes. Augusta University Health is an innovative health system, and we are proud to partner with them on this mission-critical enhancement to their radiology team and their patients.” 

Inflo Health was founded by a revolutionary radiologist, frustrated by an overworked and inefficient healthcare system, who wanted to improve the patient outcomes. As a result, a team of clinical and technical experts came together to develop large language models and NLU to read and understand radiology reports with the goal of automating identification of which patients have recommendations for additional imaging. Inflo Health then automates communication to the care team and to the patients to help ensure the follow-ups are ordered and scheduled. The Inflo Health platform streamlines the management of radiology follow-up recommendations across all imaging modalities.

About Inflo Health: We harness the power of advanced AI, large language models, and NLU to turn radiology follow-up into a stress-free process. Our proven, automated solution streamlines the management of follow-up recommendations across all imaging modalities, so you can ensure no patient falls through the care gap. With our easy-to-use, integrated platform, your team can focus on delivering top-quality patient care, while also mitigating risk, and maximizing staff efficiency.

###

AU Health is Georgia’s only public academic health center, where world-class clinicians are bringing the medicine of tomorrow to patient care today. As the primary teaching affiliate of the Medical College of Georgia, AU Health provides the most comprehensive routine-to-complex care at AU Medical Center, which houses the region’s only Level 1 trauma center, as well as Children’s Hospital of Georgia, Georgia Cancer Center, historic Roosevelt Warm Springs Rehabilitation and Specialty Hospitals, Georgia War Veterans Nursing Home, and more than 100 primary and specialty care clinics across the state.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters
August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .
August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS